Blog
Tufts Center for the Study of Drug Development reports major increase in endpoints per protocol
The Tufts Center for the Study of Drug Development (TCSD) has released data showing that between 2004 and 2012 the number of endpoints per protocol has increased from an average of eight per protocol in the earlier period to 14 endpoints in the later period. To read...
Sequester cuts scheduled for March 1st expected to impact healthcare, research
The healthcare industry, medical research and drug approval process are projected to be greatly affected by the federal budget cuts scheduled for March 1, according to a recent article on mondernhealthcare.com. The Budget Control Act of 2011, originally scheduled to...
Save the Date: April 16th Caldwell to serve on IHIF April Life Science Lunch Panel
IHIF is hosting a lunch panel on April 16th, featuring Pearl’s Diana Caldwell and other industry professionals to discuss the impact of the service sector on life sciences in Indiana.
Top 5 FDA warning letters for clinical investigators
IMARC Research, a contract research organization (CRO) recently published a list of the “Top Five FDA Warning Letter Findings for Clinical Investigators.” Warning letters are issued when FDA finds objectionable conditions upon inspection. IMARC’s top 5 noted...
Diana Caldwell, Pearl President and CEO to speak at Leadership Institute for Women
The Leadership Institute for Women: Positioning Your Business for Growth will feature Pearl Co-founder, Diana Caldwell on a panel discussion about teaming arrangements from a WBE perspective. What: Leadership Institute for Women: Positioning Your Business for Growth...